Abstract
A new method for comparing the survival of two or more groups of patients adjusting for factors distributed unevenly between the groups is presented. This is a development of previous methods, and provides a graphical counterpart to Mantel's adjusted chi-square statistic. The method can be used to retrospectively stratify for prognostic factors, and to provide additional validation and interpretation of multivariate results, including those based on Cox's proportional hazards model. Like Mantel's adjusted chi-square statistic, the method adjusts at every event, based on the numbers of patients still at risk in each of the groups, and is thus able to show up time-dependent effects: factors can be seen to be relevant during certain periods of the study only. The method presented thus allows curves to be drawn as they would have been expected to look, had the prognostic factors been evenly distributed between the groups.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gregory, W. Adjusting survival curves for imbalances in prognostic factors. Br J Cancer 58, 202–204 (1988). https://doi.org/10.1038/bjc.1988.193
Issue Date:
DOI: https://doi.org/10.1038/bjc.1988.193
This article is cited by
-
The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic Renal Cancer
BMC Cancer (2012)
-
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin’s disease is unlikely to be associated with a major increased risk of secondary MDS/AML
British Journal of Cancer (1999)